Survodutide targets glucagon and GLP-1 receptors, rather than GIP and GLP-1. Its research programme spans obesity, diabetes and liver disease. Published phase 3 papers now expand the human evidence, but these endpoints should not be treated as interchangeable. Latest published obesity trial.
These human trials evaluate an investigational pharmaceutical under controlled conditions, with different populations and endpoints. Reading their results together requires keeping those differences visible.
Phase 2 established a signal, with substantial attrition
The earlier obesity study randomised 387 adults without diabetes, of whom 386 received treatment. At 46 weeks, planned-treatment mean weight reduction reached 14.9% in the highest studied group, versus 2.8% with placebo. However, only 60.4% of treated participants completed the 46-week treatment period. Gastrointestinal events occurred in 75% of pooled active-treatment participants versus 42% with placebo. Completion and tolerability matter when interpreting a strong efficacy signal; not every discontinuation should automatically be attributed to an adverse event. Phase 2 obesity publication.
Attrition is more than a footnote. If people leave treatment or stop providing measurements, the analysis needs assumptions about outcomes that are not directly observed. An impressive average among continuing participants can answer a different question from the expected result of assigning treatment in the first place.
SYNCHRONIZE-1 supplies the larger obesity experiment
The 2026 phase 3 publication enrolled 725 adults without diabetes and followed treatment for 76 weeks. Under the treatment-regimen analysis, mean weight changes were −12.2% and −13.0% in the two active groups, compared with −5.4% on placebo. The highest-group separation using these means is 7.6 percentage points. Gastrointestinal adverse events affected 80.9% and 89.7% of active groups versus 47.9% on placebo. These are specific results under a stated analysis, not a reason to substitute a more favourable headline from another estimand. SYNCHRONIZE-1 publication.
SYNCHRONIZE-2 addresses the diabetes population
Published in October 2026, SYNCHRONIZE-2 randomised 752 adults with type 2 diabetes and overweight or obesity. At 76 weeks, treatment-regimen weight changes were −8.2% and −9.8%, versus −3.9% with placebo. The highest-group difference is 5.9 percentage points. HbA1c declined more in both active groups, while gastrointestinal adverse events affected 72.8% and 77.7% versus 38.6%. The findings extend the evidence into diabetes; comparing them with the non-diabetes trial does not isolate diabetes as the cause of a response difference. SYNCHRONIZE-2 publication.
A liver biopsy asks a different question
The 48-week phase 2 MASH trial included 293 treated participants with biopsy-confirmed disease and fibrosis stages F1–F3. Its primary endpoint was improvement in MASH without worsening fibrosis. Response proportions were 47%, 62% and 43% across active groups, versus 14% with placebo. That endpoint was improvement, not proof of complete disease resolution or prevention of cirrhosis. Nausea, diarrhoea and vomiting were more frequent with active treatment. The non-monotonic response across groups also discourages an assumption that more exposure always means greater benefit. MASH biopsy trial.
Histology provides information that body weight alone cannot supply. Even so, a tissue-based endpoint remains different from measuring future liver failure, transplantation or survival. Those clinical questions require appropriate follow-up and events; they cannot be filled in simply because an earlier marker moves in a favourable direction.
Liver-fat imaging is informative, but narrower
SYNCHRONIZE-MASLD studied 216 participants over 48 weeks. One co-primary endpoint was at least a 30% reduction in liver fat measured by MRI-PDFF. Under the treatment-regimen analysis, 68.5% with survodutide and 28.6% with placebo reached that threshold. The efficacy-analysis figures were 84.2% and 24.3%, demonstrating how analysis choice changes the reported result. The investigators identified limited duration and geographic reach as constraints. Gastrointestinal events were the most common adverse events. An imaging response is not a direct measurement of fibrosis reversal. SYNCHRONIZE-MASLD publication.
What a balanced reading preserves
The programme supports continued investigation across several human populations. It also shows why the generic phrase “liver benefits” is too imprecise: weight change, liver-fat reduction, biopsy improvement and clinical events are different claims. An honest synthesis names the measurement instead of allowing readers to assume the strongest possible meaning.
Future evidence will be most useful when it clarifies longer-term outcomes, discontinuation and uncommon harms alongside efficacy. For now, the publications justify interest in the programme while leaving clear boundaries around what has actually been demonstrated.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- Survodutide phase 2 obesity trial — Peer-reviewed randomised human trial; 2024-02-05.
- SYNCHRONIZE-1: Survodutide for obesity — Peer-reviewed phase 3 human trial; 2026-06-07.
- SYNCHRONIZE-2: Survodutide in obesity and type 2 diabetes — Peer-reviewed phase 3 human trial; 2026-10-01.
- Survodutide phase 2 trial in MASH — Peer-reviewed randomised human liver trial; 2024-06-07.
- SYNCHRONIZE-MASLD: Survodutide and liver fat — Peer-reviewed phase 3 human imaging trial; 2026-06-07.
